Steven K. Wetter - Concepedia

Author

Steven K. Wetter

Johnson & Johnson (United States)

Also Known As

Steven K Wetter, Steven K. Wetter, Wetter, S.K.

Publications

537

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)

About

Steven K. Wetter is an author at Johnson & Johnson (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	511
2	Biochemistry	3	3	92
3	Natural Sciences	2	2	69
4	Cell Biology	2	2	248
5	Chemical Biology	1	1	27

Steven K. Wetter

Publications

523

Citations

H-Index

Page 1

	Year	Citations
Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors Ronghui Lin, Sigmond G. Johnson, Peter J. Connolly, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicinePharmacological AgentTyrosine Kinase InhibitorsPharmacotherapy	2009	126
1-Acyl-1<i>H</i>-[1,2,4]triazole-3,5-diamine Analogues as Novel and Potent Anticancer Cyclin-Dependent Kinase Inhibitors: Synthesis and Evaluation of Biological Activities Ronghui Lin, Peter J. Connolly, Shenlin Huang, Journal of Medicinal Chemistry Selective Cdk1Medicinal ChemistryRepresentative Compound 3BMedicinePharmacological Agent	2005	126
The <i>In vitro</i> and <i>In vivo</i> Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases Stuart L. Emanuel, Catherine A. Rugg, Robert H. Gruninger, Cancer Research Dual InhibitorCell DeathTotal Cumulative DoseCell CycleCancer Biology	2005	122
4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation Terry V. Hughes, Stuart L. Emanuel, Amanda K. Beck, Bioorganic & Medicinal Chemistry Letters MedicineVegf-r2 InhibitorsRational Drug DesignPharmacotherapyDrug Development	2007	45
N-Hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase Peter J. Connolly, Steven K. Wetter, Kimberly N. Beers, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesMechanism Of Action	1999	42
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity Terry V. Hughes, Guozhang Xu, Steven K. Wetter, Bioorganic & Medicinal Chemistry Letters Biological ActivityMedicinal ChemistryBiochemistryNatural SciencesMedicine	2008	27
3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation Ronghui Lin, Yanhua Lü, Steven K. Wetter, Bioorganic & Medicinal Chemistry Letters Cyclin-dependent Kinase InhibitorsBiochemistryMedicinePharmacological AgentHeterocycle Chemistry	2005	23
Synthesis and progesterone receptor binding affinity of substituted 1-phenyl-7-benzyl-4,5,6,7-tetrahydro-1-indazoles Peter J. Connolly, Steven K. Wetter, Kimberly N. Beers, Bioorganic & Medicinal Chemistry Letters PharmacologyProgesterone ReceptorPharmacological AgentFunctional Selectivity	1997	12

Page 1